HMGB1 and cancer: Our findings showed that ICM treatment inhibited the phosphorylation of constitutively activated STAT3, suggesting that targeting the nucleo-cytoplasmic translocation of HMGB1 may offer a potential therapeutic strategy against cancers with constitutive STAT3 activation.